@article{37a78292588b4a4197b8ad3a12a6ce44,
title = "Combating resistance while maintaining innovation: The future of antimicrobial stewardship",
abstract = "Antimicrobial resistance represents a significant global health threat. However, a commercial model that does not offer a return on investment resulting in a lack of investment in antibiotic R&D, means that the current pipeline of antibiotics lacks sufficient innovation to meet this challenge. Those responsible for defining, promoting and monitoring the rationale use of antibiotics (the antimicrobial stewardship programme) are key to addressing current shortcomings. In this personal perspective, we discuss the future role stewardship can play in stimulating innovation, a need to move away from a pharmacy budget dominated view of antibiotic use, and the impact of the ever-increasing sophistication and interdisciplinary nature of antimicrobial control programs. Changes are needed to optimize clinical outcomes for patients.",
keywords = "antibiotic cost, antimicrobial stewardship, novel mechanism antibiotics",
author = "Vickers, {Richard J.} and Matteo Bassetti and Clancy, {Cornelius J.} and Garey, {Kevin W.} and Greenberg, {David E.} and Nguyen, {Minh Hong} and David Roblin and Tillotson, {Glenn S.} and Wilcox, {Mark H.}",
note = "Funding Information: RJ Vickers is an employee and holds share options in Summit Therapeutics. M Bassetti has received personal fees from Angelini, AstraZeneca, Bayer, Biomerieux, Cidara, Cubist, Pfizer, Melinta Therapeutics, Menarini, MSD, Nabriva, Paratek, Roche, Shionogi, Tetraphase, The Medicines Company and Astellas Pharma Inc. CJ Clancy has been awarded investigator initiated research grants from Astellas, Merck, Melinta, and Cidara for projects unrelated to this study, served on advisory boards or consulted for Astellas, Merck, the Medicines Company, Cidara, Scynexis, Shionogi, Qpex and Needham & Company, and spoken at symposia sponsored by Merck and T2Biosystems. KW Garey has received personal fees from Merck, Paratek, Biomerieux and Seres and received grants from Summit Therapeutics, Merck, Paratek and Tetraphase. DE Greenberg has received grants from Shionogi. MH Nguyen has been awarded investigator initiated research grants from Astellas, Merck, Melinta and Cidara for projects unrelated to this study, and served on advisory boards for Astellas, Merck, the Medicines Company, Scynexis and Shionogi. D Roblin is an employee and holds share options in Summit Therapeutics. GT has received personal fees from Melinta, Shionogi, KBP Biosciences, Spero, Sinsa Pharmaceuticals and TechLabs. MH Wilcox has received personal feSEes from Abbott Laboratories, Actelion, Antabio, AiCuris, Alere, Astellas, AstraZeneca, Bayer, Biom{\`e}rieux, Cambimune, Cerexa, Cubist, Da Volterra, The European Tissue Symposium, Ferring, The Medicines Company, Menarini, Merck, Meridian, Motif Biosciences, Nabriva, Paratek, Pfizer, Phico Therapeutics, Qiagen, Roche, Seres, Spero, Surface Skins, Sanofi-Pasteur, Summit, Synthetic Biologics and Valneva and has received grants from Abbott, Actelion, Astellas, Biom{\`e}rieux, Cubist, Da Volterra, Merck, MicroPharm, Morphochem AG, Motif Biosciences, Nabriva, Paratek, Pfizer, Sanofi-Pasteur, Seres, Summit and The European Tissue. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: {\textcopyright} 2019 The Authors.",
year = "2019",
doi = "10.2217/fmb-2019-0227",
language = "English (US)",
volume = "14",
pages = "1331--1341",
journal = "Future Microbiology",
issn = "1746-0913",
publisher = "Future Medicine Ltd.",
number = "15",
}